- Status:
- Red
- Decision Date:
- February 2022
Comments
RED: NICE TA835 (replaces TA759) - Fostamatinib for treating refractory chronic immune thrombocytopenia.
ICB commissioned. (Decision date - November 2022)
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
search again